Author

Ana H.C. Guimarães

Observed names: A. Guimarães, A. H. C. GUIMARÃES, A. H. C. Guimarães, A.H.C. GUIMARAES, A.H.C. GUIMARÃES, A.H.C. Guimarães, Ana Guimarães, Ana H. C. Guimarães, Ana H. Guimaraes, Ana H.C. Guimarães, Guimarães, Ana H C

Observed institutions: University of Copenhagen, University of British Columbia, Netherlands Organisation for Applied Scientific Research, Universität Ulm, National and Kapodistrian University of Athens, Erasmus MC, Copenhagen University Hospital, Rigshospitalet, NYU Langone Health, Amsterdam University Medical Centers, Cardialysis (Netherlands), Amsterdam Cardiovascular Sciences, European Cardiovascular Research Institute, University of Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Icahn School of Medicine at Mount Sinai

OpenAlex ID: A5111487605

A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement

2019 · George D. Dangas, Jan G.P. Tijssen, et al. · New England Journal of Medicine · 562

PDF

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

2019 · Ole De Backer, George D. Dangas, et al. · New England Journal of Medicine · 302

PDF

High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke

2005 · F.W.G. LEEBEEK, M.P.J. VAN GOOR, et al. · Journal of Thrombosis and Haemostasis · 108

Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study

2016 · Stephan Windecker, Jan Tijssen, et al. · American Heart Journal · 103

PDF

Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests

2012 · D.C. RIJKEN, E.L. KOCK, et al. · Journal of Thrombosis and Haemostasis · 91

Hypofibrinolysis is a risk factor for arterial thrombosis at young age

2009 · Ana H. C. Guimarães, Emile L. E. De Bruijne, et al. · British Journal of Haematology · 83

PDF

The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC study

2009 · E.L.E. DE BRUIJNE, A. GILS, et al. · Journal of Thrombosis and Haemostasis · 72

Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays

2004 · A. H. C. Guimarães, N. H. van Tilburg, et al. · British Journal of Haematology · 52

Thrombin activatable fibrinolysis inhibitor is associated with severity and outcome of severe meningococcal infection in children

2008 · M. EMONTS, E. L. E. DE BRUIJNE, et al. · Journal of Thrombosis and Haemostasis · 49

PDF

Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome

2009 · Jildou Hoekstra, Ana H. C. Guimarães, et al. · Blood · 46

TAFI and Pancreatic Carboxypeptidase B Modulate In Vitro Capillary Tube Formation by Human Microvascular Endothelial Cells

2007 · Ana H.C. Guimarães, Nancy Laurens, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 26

PDF

High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease

2010 · Emile L.E. de Bruijne, Ann Gils, et al. · Thrombosis Research · 24

PDF

A new functional assay of thrombin activatable fibrinolysis inhibitor

2005 · A.H.C. GUIMARÃES, R.M. BERTINA, et al. · Journal of Thrombosis and Haemostasis · 24

Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner

2003 · Ana Guimarães, Dingeman Rijken · Thrombosis and Haemostasis · 19

Migration of the activation peptide of thrombin‐activatable fibrinolysis inhibitor (TAFI) during SDS–polyacrylamide gel electrophoresis

2004 · A.H.C. Guimarães, M.M. Barrett‐Bergshoeff, et al. · Journal of Thrombosis and Haemostasis · 16

ID: 256 Evidence for an enhanced fibrinolytic capacity in cirrhosis measured with a new global fibrinolysis test in whole blood.

2006 · D. Rijken, E. Kock, et al. · Journal of Thrombosis and Haemostasis · 2

Evidence for an Enhanced Fibrinolytic Capacity in Liver Cirrhosis Measured with a New Global Fibrinolysis Test in Whole Blood.

2006 · Frank W.G. Leebeek, Edith L. Kock, et al. · Blood · 1

ID: 141 Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models. Sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI).

2006 · A. Guimarães, M. Barrett-Bergshoeff, et al. · Journal of Thrombosis and Haemostasis

Modulation of the plasminogen system by thrombin activatable fibrinolysis inhibitor (TAFI)

2006 · Ana H.C. Guimarães · EUR Research Repository (Erasmus University Rotterdam)

Works count: 20

Citation count: 1,580

H-index: 15

I10-index: 15